Alto Neuroscience's ALTO-101 Fails Phase 2 Study for Schizophrenia, Shifts Focus to ALTO-207
ANRO has more than doubled off its 52-week low of $1.6.
Summary
Alto Neuroscience announced that its ALTO-101 drug candidate failed to meet primary endpoints in a Phase 2 study for cognitive impairment associated with schizophrenia, leading the company to discontinue independent development and prioritize its ALTO-207 program.
Key Events · Product Development and Regulatory · ANRO
-
ALTO-101 Phase 2 Study Failure
ALTO-101 did not achieve statistical significance on primary EEG or cognitive endpoints in its Phase 2 proof-of-concept study for cognitive impairment associated with schizophrenia.
-
Strategic Pipeline Shift
The company will not independently advance ALTO-101 in CIAS and plans to explore partnering opportunities for a modified-release oral formulation of the drug.
-
Prioritization of ALTO-207
Resources will be focused on ALTO-207, which remains on track to initiate a Phase 2b clinical trial in the first half of 2026 for treatment-resistant depression.
-
Financial Position Highlighted
Alto Neuroscience emphasized its strong cash position of $275 million to support ongoing operations and pipeline advancements.
Analysis · ANRO · Life Sciences
The failure of ALTO-101 in its Phase 2 proof-of-concept study represents a significant setback for Alto Neuroscience's pipeline, as it directly impacts a key drug candidate. While the company observed some directional improvements and a favorable tolerability profile, the lack of statistical significance on primary endpoints means ALTO-101 will not be independently advanced for CIAS. This forces a strategic pivot, with the company now prioritizing ALTO-207 for treatment-resistant depression and seeking partners for ALTO-101. Investors will closely monitor the progress of ALTO-207 and any potential partnering deals, as well as the company's cash burn given the $275 million cash position.
At the time of this filing, ANRO was trading at $22.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $747.8M. The 52-week trading range was $1.60 to $25.17. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.